CY1118933T1 - Anti-cxcr1 συνθεσεις και μεθοδοι - Google Patents

Anti-cxcr1 συνθεσεις και μεθοδοι

Info

Publication number
CY1118933T1
CY1118933T1 CY20171100385T CY171100385T CY1118933T1 CY 1118933 T1 CY1118933 T1 CY 1118933T1 CY 20171100385 T CY20171100385 T CY 20171100385T CY 171100385 T CY171100385 T CY 171100385T CY 1118933 T1 CY1118933 T1 CY 1118933T1
Authority
CY
Cyprus
Prior art keywords
cxcr1
methods
oncogenic
present
compositions
Prior art date
Application number
CY20171100385T
Other languages
English (en)
Inventor
Max S Wicha
Christophe Ginestier
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of CY1118933T1 publication Critical patent/CY1118933T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους θεραπευτικής αγωγής καρκίνου με χορήγηση ενός αναστολέα IL8-CXCR1 οδού (π.χ., ενός αντι-CXCR1 αντισώματος ή Repertaxin) μόνου του ή σε συνδυασμό με έναν επιπρόσθετο χημειοθεραπευτικό παράγοντα έτσι ώστε μη-ογκογόνα και ογκογόνα καρκινικά κύτταρα σε ένα υποκείμενο να σκοτώνονται. Η παρούσα εφεύρεση παρέχει επίσης συνθέσεις και μεθόδους για ανίχνευση της παρουσίας και απομόνωσης βλαστικών κυττάρων συμπαγούς όγκου σε έναν ασθενή (π.χ., βάσει της παρουσίας CXCR1 ή FBXΟ21).
CY20171100385T 2008-11-11 2017-03-29 Anti-cxcr1 συνθεσεις και μεθοδοι CY1118933T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11345808P 2008-11-11 2008-11-11
PCT/US2009/064041 WO2010056753A1 (en) 2008-11-11 2009-11-11 Anti-cxcr1 compositions and methods

Publications (1)

Publication Number Publication Date
CY1118933T1 true CY1118933T1 (el) 2018-01-10

Family

ID=42170302

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100385T CY1118933T1 (el) 2008-11-11 2017-03-29 Anti-cxcr1 συνθεσεις και μεθοδοι

Country Status (26)

Country Link
US (3) US8940301B2 (el)
EP (2) EP2356462B1 (el)
JP (3) JP5716180B2 (el)
KR (3) KR20110093893A (el)
CN (3) CN102272599B (el)
AU (1) AU2009314141B2 (el)
BR (1) BRPI0921150B1 (el)
CA (1) CA2743305C (el)
CY (1) CY1118933T1 (el)
DK (1) DK2356462T3 (el)
EA (1) EA023466B1 (el)
ES (1) ES2623128T3 (el)
HK (3) HK1206256A1 (el)
HR (1) HRP20170463T1 (el)
HU (1) HUE032623T2 (el)
IL (1) IL212822A (el)
LT (1) LT2356462T (el)
MX (2) MX2011005007A (el)
NZ (2) NZ625440A (el)
PL (1) PL2356462T3 (el)
PT (1) PT2356462T (el)
RS (1) RS55784B1 (el)
SG (1) SG10201701954QA (el)
SI (1) SI2356462T1 (el)
WO (1) WO2010056753A1 (el)
ZA (1) ZA201103416B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55784B1 (sr) 2008-11-11 2017-07-31 Univ Michigan Regents Anti-cxcr1 kompozicije i postupci
GB201106870D0 (en) * 2011-04-26 2011-06-01 Univ Belfast Marker
US10598653B2 (en) * 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
EP2831112A1 (en) * 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
KR102190322B1 (ko) * 2013-04-29 2020-12-11 오제데2 파르마 암줄기세포 암에 대한 새로운 치료적 진단적 전략으로서 o-아세틸화된-gd2 갱글리오사이드 타겟화
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
EP3518898A4 (en) 2016-10-03 2020-06-17 The Children's Medical Center Corporation PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
CA3044030A1 (en) * 2016-11-17 2018-05-24 Nantbio, Inc. Validation of inferred anticancer pathways
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10100275B2 (en) * 2017-03-16 2018-10-16 King Faisal Specialist Hospital & Research Centre Method for generating human multipotent mammary stem cells from normal primary breast luminal cells
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
RU2702910C2 (ru) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения количества стволовых клеток рака молочной железы
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
RU2700695C2 (ru) * 2019-02-27 2019-09-19 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения клоногенной активности стволовых клеток рака молочной железы
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
KR102558989B1 (ko) * 2020-01-10 2023-07-21 라이즈 바이오파마슈티컬즈, 인코포레이티드 (베이징) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
CN114075286A (zh) * 2020-08-21 2022-02-22 张家港博泽利斯生物技术有限公司 一种抗人cxcr1蛋白单克隆抗体的制备方法
WO2023032957A1 (ja) * 2021-08-30 2023-03-09 学校法人東京薬科大学 がんの予防および／または治療のための医薬組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN1202206A (zh) * 1995-11-16 1998-12-16 M·W·达姆 用于定量测定体液中肿瘤细胞的方法和适于此方法的试验试剂盒
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
KR20000049096A (ko) 1996-10-11 2000-07-25 린다 에스. 스티븐슨 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법
CA2283267A1 (en) 1997-03-07 1998-09-11 Clare Chemical Research Llc Fluorometric detection using visible light
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
EP1461023A4 (en) 2001-12-07 2005-08-31 Univ Michigan PROSPECTIVE IDENTIFICATION AND CHARACTERIZATION OF BREAST CANCER STEM CELLS
US7919083B2 (en) * 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
PL1629088T3 (pl) * 2003-05-30 2012-06-29 Agensys Inc Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20050142136A1 (en) * 2003-10-23 2005-06-30 Lary Suva Anti-interleukin 8 therapy for tumor osteolysis
CA2554779A1 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005103711A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
EP1745032B1 (en) 2004-05-12 2013-07-31 Merck Sharp & Dohme Corp. CXCR1 and CXCR2 chemokine antagonists
GB0417740D0 (en) 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
EP1945754B1 (en) * 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
CL2007001142A1 (es) * 2006-04-21 2008-01-25 Smithkline Beecham Corp Compuestos derivados de sulfona, antagonistas del receptor il-8; procedimiento de preparacion;compuestos intermediarios;composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva cronica, dermatitis, psoriasis, alzheimer, aterosclerosis, osteoporosis.
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
JP5311439B2 (ja) * 2006-12-27 2013-10-09 日本メナード化粧品株式会社 皮膚の状態を評価する方法及びその用途
CN101126758A (zh) * 2007-09-06 2008-02-20 江苏省肿瘤医院 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法
US20110111434A1 (en) * 2008-07-15 2011-05-12 Huang Emina H Colon stem cells associated with colitisand colorectal cancer and methods of use
RS55784B1 (sr) 2008-11-11 2017-07-31 Univ Michigan Regents Anti-cxcr1 kompozicije i postupci

Also Published As

Publication number Publication date
CN104623664A (zh) 2015-05-20
JP2016065082A (ja) 2016-04-28
JP2014037427A (ja) 2014-02-27
CA2743305A1 (en) 2010-05-20
HRP20170463T1 (hr) 2017-05-19
MX2011005007A (es) 2011-07-28
NZ602369A (en) 2015-02-27
CN104623664B (zh) 2018-08-07
SI2356462T1 (sl) 2017-05-31
EP2356462A4 (en) 2012-09-19
KR20150065930A (ko) 2015-06-15
JP5909783B2 (ja) 2016-04-27
ZA201103416B (en) 2012-08-29
AU2009314141B2 (en) 2013-11-07
BRPI0921150B1 (pt) 2022-05-10
CN104634972B (zh) 2017-06-13
EP3153862A1 (en) 2017-04-12
KR101588547B1 (ko) 2016-01-28
PT2356462T (pt) 2017-04-07
KR20140132412A (ko) 2014-11-17
US20150160227A1 (en) 2015-06-11
US9606124B2 (en) 2017-03-28
NZ625440A (en) 2016-01-29
KR20110093893A (ko) 2011-08-18
BRPI0921150A2 (pt) 2020-11-17
CN102272599A (zh) 2011-12-07
HK1161350A1 (en) 2012-08-24
RS55784B1 (sr) 2017-07-31
EP2356462A1 (en) 2011-08-17
US8940301B2 (en) 2015-01-27
EA201100779A1 (ru) 2011-12-30
HK1206421A1 (en) 2016-01-08
PL2356462T3 (pl) 2017-07-31
US20100136031A1 (en) 2010-06-03
CN104634972A (zh) 2015-05-20
LT2356462T (lt) 2017-03-10
ES2623128T3 (es) 2017-07-10
EP2356462B1 (en) 2017-01-04
JP2012508384A (ja) 2012-04-05
HK1206256A1 (en) 2016-01-08
US20150094362A1 (en) 2015-04-02
EA023466B1 (ru) 2016-06-30
CA2743305C (en) 2017-04-04
US10557850B2 (en) 2020-02-11
JP5716180B2 (ja) 2015-05-13
HUE032623T2 (hu) 2017-10-30
WO2010056753A1 (en) 2010-05-20
MX351889B (es) 2017-11-01
SG10201701954QA (en) 2017-05-30
IL212822A (en) 2017-05-29
DK2356462T3 (en) 2017-02-27
IL212822A0 (en) 2011-07-31
CN102272599B (zh) 2015-01-14
AU2009314141A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CY1118933T1 (el) Anti-cxcr1 συνθεσεις και μεθοδοι
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1123938T1 (el) Συνδυασμος αντισωματος αντι-cd20 και εκλεκτικου αναστολεα κινασης p13
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1121025T1 (el) ΑΝΤΙΣΩΜΑ ANTI-cMET
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
CY1117340T1 (el) Κυτταροτοξικα παραγωγα βενζοδιαζεπινης
CY1117587T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1124140T1 (el) Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης
CY1116488T1 (el) Αντισωματα anti-προπερδινης
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
BR112015020466A2 (pt) inibidores de cdc7
BR112013000651A2 (pt) combinações de inibidores de cinase para o tratamento de câncer.